Albireo pharma：Ipsen completes acquisition of Albireo
Ipsen completes acquisition of Albireo
2023年3月2日—PARIS,FRANCE,3March2023–Ipsen(Euronext:IPN:ADR:IPSEY)todayannouncedithascompletedtheacquisitionofAlbireoPharma,Inc., ...。其他文章還包含有：「AlbireoPharmaInc(ALBO)」、「AlbireoPharma」、「AlbireoPharma」、「AlbireoPharma」、「IpsenconcludespurchaseofAlbireoPharma」、「IpsentoacquireAlbireoacceleratinggrowthinrare...」、「Ipsen–improvingpatienthealthoutcomes」
查看更多 離開網站
Albireo Pharma Inc (ALBO)
https://invest.cnyes.com
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to ...
Albireo Pharma
https://www.moneydj.com
Albireo Pharma, Inc.(ALBO.US)前身為Biodel Inc.(BIOD.US)，總部位於美國麻州波士頓，為一家生物製藥公司，專注於開發及商品化創新膽酸調節器，藉以治療罕見小兒肝臟 ...
Albireo Pharma
https://www.moneydj.com
其候選產品包含口服施藥IBAT抑制劑A4250，現處臨床試驗phase 2，用於治療遺傳性肝內膽汁鬱積，以及臨床開發階段的其他小兒膽汁鬱積性肝臟疾病和失調。
Albireo Pharma
https://cn.linkedin.com
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver ...
Ipsen concludes purchase of Albireo Pharma
https://www.pharmaceutical-tec
French biopharmaceutical firm Ipsen has concluded the purchase of US-based Albireo Pharma, expanding its rare disease portfolio.
Ipsen to acquire Albireo accelerating growth in rare ...
https://www.ipsen.com
Albireo is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases.
Ipsen – improving patient health outcomes
https://www.ipsen.com
Ipsen is a global biopharmaceutical company, improving patients' lives through research and innovation in oncology, rare disease & neuroscience.